Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition. Shares of Allergan, which makes wrinkle treatment Botox, fell 13.1 percent after the company said mid-stage trial results of Darpin did not warrant an immediate move into far larger late-stage trials. Regeneron shares closed up 10.3 percent. If eventually approved, Darpin would also compete with Roche Holding AG's, Lucentis, to treat age-related macular degeneration - the most common form of blindness in the elderly.
Help employers find you! Check out all the jobs and post your resume.
Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition. Shares of Allergan, which makes wrinkle treatment Botox, fell 13.1 percent after the company said mid-stage trial results of Darpin did not warrant an immediate move into far larger late-stage trials. Regeneron shares closed up 10.3 percent. If eventually approved, Darpin would also compete with Roche Holding AG's, Lucentis, to treat age-related macular degeneration - the most common form of blindness in the elderly.
Help employers find you! Check out all the jobs and post your resume.
